| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:BI-665915
CAS:1360550-04-4
Package:100mg/RMB 19500;50mg/RMB 15300;25mg/RMB 11700
|
2-[4-[3-[(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]-N,N-dimethylacetamide manufacturers
- BI-665915
-
- $2800.00 / 100mg
-
2025-08-21
- CAS:1360550-04-4
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 2-[4-[3-[(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]-N,N-dimethylacetamide Basic information |
| Product Name: | 2-[4-[3-[(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]-N,N-dimethylacetamide | | Synonyms: | 2-[4-[3-[(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]-N,N-dimethylacetamide;BI 665915
(BI665915;BI-665915);1H-Pyrazole-1-acetamide, 4-[3-[(1R)-1-[4-(2-amino-5-pyrimidinyl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]-N,N-dimethyl- | | CAS: | 1360550-04-4 | | MF: | C24H26N8O2 | | MW: | 458.52 | | EINECS: | | | Product Categories: | | | Mol File: | 1360550-04-4.mol | ![2-[4-[3-[(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]-N,N-dimethylacetamide Structure](CAS/20180601/GIF/1360550-04-4.gif) |
| | 2-[4-[3-[(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]-N,N-dimethylacetamide Chemical Properties |
| Boiling point | 738.8±70.0 °C(Predicted) | | density | 1.41±0.1 g/cm3(Predicted) | | pka | 3.15±0.10(Predicted) |
| | 2-[4-[3-[(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]-N,N-dimethylacetamide Usage And Synthesis |
| Description | BI-665915 is a 5-lipoxygenase activating protein inhibitor. | | Uses | BI 665915 is an orally active and potent 5-lipoxygenase-activating protein (FLAP) inhibitor. BI 665915 inhibits FLAP production that blocks LTB4 biosynthesis in mice. BI 665915 is promising for research of various inflammatory diseases, including respiratory and cardiovascular diseases[1]. | | References | [1] Takahashi H, et al. Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(R)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1, 2, 4] oxadiazol-5-yl)-pyrazol-1-yl]-N, N-dimethyl-acetamide (BI 665915)[J]. Journal of Medicinal Chemistry, 2015, 58(4): 1669-1690. |
| | 2-[4-[3-[(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]-N,N-dimethylacetamide Preparation Products And Raw materials |
|